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I
rritable bowel syndrome (IBS) is a common gastrointestinal disorder which accounts for about 40% of all gastroenterology outpatient consultations. 1 Although an alteration of the brain-gut axis is considered to have a fundamental role, 2 gut mucosal inflammation is certainly important in the complex pathogenesis of IBS. 3 In fact, several studies have shown an increased number of immunocytes both in the lamina propria and in the epithelium of mucosal biopsy specimens from IBS patients. 4 -10 Lamina propria and intraepithelial lymphocytes, 5 ,10 mast cells, 4, 7, 9 and macrophages 11 are among the immunocytes involved in mucosal inflammation in IBS, and a role for a previous infectious enteritis in determining this inflammation has been established. 11, 12 However, it is also known that dietary factors might be important in the pathogenesis of IBS 3 and the same inflammatory cells, together with eosinophils, are the immunologic effectors of food hypersensitivity (FH). [13] [14] [15] [16] [17] As many symptoms of IBS are common to FH-abdominal pain and/or discomfort, bloating, alteration of bowel habitsdifferential diagnosis between these 2 conditions is difficult.
In this study involving IBS patients, we aimed to: (1) evaluate the frequency of FH diagnosis; and (2) investigate the diagnostic accuracy of 3 fecal markers-calprotectin, tryptase, and eosinophil cationic protein-in FH diagnosis.
Methods
One hundred sixty patients (127 females, 33 males, age range 18 -60 years, median age 33 years), who had been consecutively referred for IBS as outpatients to 2 internal medicine clinics (University Hospital of Palermo and Ospedali Civili Riuniti of Sciacca, both in Italy) from February 2007 to June 2009, completed this study.
The inclusion criteria were identical to those recently used 18 : (1) age Ͼ 17 years, (2) no previous referral to our clinics, and (3) diagnosis of IBS. Patients with a diagnosis of organic gastrointestinal disease were excluded.
IBS diagnosis was based on the Rome II criteria for functional gastrointestinal disorders 19 and organic gastrointestinal disorders were excluded by an accurate work-up (see Supplementary Methods).
After inclusion, the patients underwent a clinical evaluation, which included a detailed family and personal clinical history and a physical examination. A predesigned questionnaire, regarding the type and severity of the symptoms, was administered to all patients.
None of the enrolled patients were taking any medication at the time of the study.
The Ethics Committee of the University Hospital of Palermo approved the study and all patients gave their informed consent to participate.
Healthy and Disease Control Groups
Two control groups were selected to compare fecal assay values. One was composed of 40 patients with various gastrointestinal diseases (30 females, 10 males, age range 18 -59 years, median 31 years): celiac disease (n ϭ 16), active ileocolonic Crohn's disease (n ϭ 18), and intestinal giardiasis (n ϭ 6), diagnosed according to standard serologic, endoscopy, and histology criteria. The other group was composed of 50 healthy volunteers (38 females, 12 male, age range 18 -60 years, median 30 years).
Study Protocol
After enrollment in the study, the patients completed the "symptom severity" questionnaire (see Supplementary Methods) and underwent serum total and food allergen-specific IgE determination, together with the fecal assays. The diagnostic tests were performed by different operators, unaware of the clinical history of the patients and the results of the other tests.
The study design was identical to one recently described. 18 In brief, patients were observed for a 4-week run-in period. After this they underwent a 4-week elimination diet without cow's milk and its derivatives, wheat, egg, tomato, and chocolate. Patients self-reporting FH were also asked to avoid ingestion and/or contact with the food(s) causing symptoms. The patients wrote a dietary diary and adherence to the elimination diet was evaluated by trained dieticians. Patients who referred a symptom and/or sign improvement after the elimination diet period underwent a double-blind placebo-controlled oral food challenge (DBPC), first with cow's milk proteins and then with wheat proteins. 20 After FH had been excluded or confirmed, all IBS patients were invited to continue the follow-up with regular visits every 6 months for 2 years. Particular attention was paid when excluding celiac disease diagnosis in FH patients (see Supplementary Methods).
Double-Blind Placebo-Controlled Challenges
DBPC for cow's milk and wheat were performed as previously described 18, 20 (see Supplementary Methods).
Serum Total IgE and Food Allergen-Specific IgE Antibodies
Serum samples from all patients were collected and analyzed for serum total IgE and food allergen-specific IgE antibodies by using the Phadia CAP-system (Phadia, Uppsala, Sweden). The following common food allergens were tested: egg, cow's milk, soy, peanut, wheat, tomato, and fish. Levels greater than or equal to 0.35 kU/L (level 1 on the specific IgE scale) were considered positive. Total IgE was also determined by the same method with a detection limit of 2 kU/L and an upper limit of 5000 kU/L. The normal limit for total IgE was 100 kU/L.
Preparation of Stool Samples
Patients were instructed to defecate directly into a polystyrene container (diameter 15 cm, depth 12 cm). Stool samples obviously contaminated with urine were excluded from analysis. For details and methods of tryptase, eosinophil cationic protein (ECP) and calprotectin assays, see Supplementary Methods.
Statistical Analysis
The 2 test was used for frequency comparison. Range and median values were calculated for each stool assay. Value comparison of the fecal assays was performed using the MannWhitney test. The Wilcoxon rank-sum test was used to compare the symptoms score before and after the diet treatment. Tables were constructed for frequency and percentage. The sensitivity, specificity, and diagnostic accuracy of food-specific IgE and fecal assays, along with their 95% confidence intervals, were calculated by standard statistical methods. 21 To minimize type I errors, P Ͻ .05 was considered statistically significant. All statistical analyses were performed using the SPSS 11.0 statistical package (Systat Software, Inc, Chicago, IL).
Results
During the study period, a total of 198 patients fulfilled the Rome II criteria for IBS diagnosis, but the clinical work-up demonstrated that 38 of them suffered from organic diseases (15 with celiac disease, 10 lactose intolerance, 5 small bowel bacterial overgrowth, 3 large colon adenoma Ͼ3 cm and high degree dysplasia, 3 colon cancer, and 2 intestinal giardiasis).
After the 4 weeks of run-in observation period, the remaining 160 patients underwent elimination diet. Table 1 summarizes the number of patients with an improved (score reduction Ͼ50), unchanged or worsened (score increase Ͼ50) symptom score on elimination diet. In the 90 patients with unchanged or worsened symptoms on elimination diet, a diagnosis of IBS unrelated to FH was made. The other 70 patients showing a significant reduction in symptom score on elimination diet underwent DBPC challenges. Thirty patients were positive for both cow's milk and wheat protein challenges, 6 were positive exclusively for cow's milk challenge, and 4 were positive exclusively for wheat challenge. In total, 40 patients were positive for DBPC food challenges. In all DBPC-positive patients, symptoms (abdominal pain, bloating, diarrhea, constipation, etc) reappeared after a median period of 2.5 days (range 1-8 days) after commencing the challenge with cow's milk or wheat proteins. Twenty-four of these 40 patients did not complete the challenge period with the "active food" due to the severity of symptoms. None of these patients reacted on placebo administration.
The 40 patients with positive DBPC challenges to cow's milk and/or wheat proteins fulfilled the Rome II criteria for IBS diagnosis and were diagnosed with FH.
The other 30 patients, who improved on elimination diet, did not react to the DBPC challenges; these subjects also underwent open challenges with other foods and did not react. Consequently, they were diagnosed with IBS not related to FH.
Of the whole group composed of 160 IBS patients, 40 subjects (25%) had a final diagnosis of FH and significantly improved or were cured on the elimination diet. Figure 1 summarizes the results, according to the study design.
According to the results of the elimination diet and the subsequent DBPC challenges, the patients were then divided into 2 subgroups: group A (FH), including the subjects with scores improved on elimination diet and positive to DBPC challenge with cow's milk and/or wheat proteins (n ϭ 40) and group B (IBS not related to FH), including the subjects with scores unchanged or worsened on elimination diet and the patients with negative DBPC challenge for cow's milk and wheat proteins (n ϭ 120).
Patients of group A and group B did not differ for sex, age, symptom severity score at entry to the study, clinical characteristics (frequency of predominant diarrhea or constipation or alternating bowel habits), or frequency of associated atopy. However, the duration of IBS symptoms was significantly higher in patients with FH (mean Ϯ SD: 11.4 Ϯ 4.2 vs 6.4 Ϯ 5.2 years; P Ͻ .001). Furthermore, the FH patients showed a higher frequency of self-perceived food intolerance (32 of 40 vs 24 of 120; P ϭ .01) and of history of food hypersensitivity during infancy (10 of 40 vs 9 of 120; P ϭ .02). Twenty-two of forty (55%) FH patients showed the DQ2 or DQ8 haplotypes. Figure 2 shows median and first and third quartile values of fecal tryptase in the patients of group A and group B, as well as in the 2 control groups ("healthy" and "disease" controls). Tryptase values were significantly higher in FH patients than in patients with IBS not related to FH (P Ͻ .001) and healthy controls (P Ͻ .001); whereas there was no difference between FH patients and "disease" controls. Patients with IBS not related to FH had tryptase values significantly higher than healthy controls (P Ͻ .02) and significantly lower than "disease controls" (P Ͻ .002).
A similar pattern was seen for ECP ( Figure 3 ). Values were significantly higher in FH patients than in IBS patients not related to FH (P Ͻ .0001) and healthy controls (P Ͻ .0001); "disease controls" showed values significantly higher than FH patients. Patients with IBS not related to FH had ECP values similar to healthy controls and significantly lower than "disease controls" (P Ͻ .0001).
As regards calprotectin values, there was no difference between IBS patients with FH and those with IBS unrelated to FH, nor between these 2 groups and "healthy" controls. However, "disease controls" showed values significantly higher than the other groups.
No differences in the values of the 3 fecal markers were found between patients with predominant constipation and patients with predominant diarrhea within group A and group B (see Supplementary Table 1) . Table 2 shows the number of positive and negative results of the immunologic assays in the IBS patients and in the healthy and "disease" controls. According to these results, Table 3 shows the sensitivity, specificity, and diagnostic accuracy of the immunologic assays in the diagnosis of FH in patients with a clinical presentation of IBS. Fecal ECP assay showed the highest sensitivity, specificity, and diagnostic accuracy among the assays performed. ECP sensitivity was higher than those of tryptase ( 2 7.2; P ϭ .01) and calprotectin ( 2 6; P ϭ .02). ECP specificity was high: 91% in the IBS group and no false positive results among healthy subjects; it was significantly higher than those of tryptase ( 2 4; P ϭ .05), calprotectin ( 2 3.9; P ϭ .05), and food-specific IgE ( 2 3.9; P ϭ .05). However, high values of ECP were also found in the "disease" controls, mainly in patients with chronic inflammatory bowel disease and intestinal parasitosis.
It was noteworthy that 8 of the 16 FH patients negative for serum specific IgE showed elevated fecal ECP values.
All patients included in the study were followed up for a 2-year period, during which they were reassessed at intervals of 6 months. FH patients continued to follow an elimination diet with the exclusion of the foods causing the IBS symptoms and all referred the persistent disappearance of symptoms or a consistent improvement. Symptom score at entry to the study was 365 Ϯ 75, at 6 months 170 Ϯ 55, at 12 months 160 Ϯ 45, at 18 months 140 Ϯ 60, at 24 months 145 Ϯ 45. Occasional ingestion of the eliminated foods always caused the recurrence of the IBS symptoms. Furthermore, all patients referred multiple hypersensitivity to other foods, which we evaluated with elimination diets and open challenges. Apart from cow's milk and wheat, the following foods caused IBS-like symptoms: egg (18 cases), tomato (14 cases), soy (5 cases), yeast (6 cases), pork (3 cases), prawn (4 cases), fish (5 cases), celery (3 cases), olive (2 cases), nuts (3 cases), carrot (2 cases), and meat (3 cases).
During the follow-up, some patients underwent further examinations: colonoscopy (5 cases), esopho-gastroscopy and duodenal biopsies (8 cases)-which were all negative. Serum assays for celiac disease (anti-tissue transglutaminase [tTG] and anti-endomisyum antibodies) were regularly repeated every 6 months in all FH patients and were always negative.
Ninety-nine of the IBS patients unrelated to FH completed the 2-year follow-up and 21 were lost. In most of these subjects IBS symptoms persisted periodically, despite several treatments. None of them were found to be suffering from an "organic" cause of symptoms.
Discussion
IBS is a complex disease and genetic, neurobiological, and psychosocial factors are involved in its pathogenesis. Recently, the role of microscopic inflammation and immune activation in the intestinal mucosa has been elucidated. 3, 5, 22 Gastrointestinal infections are more likely to initiate IBS-like symptoms 23 inducing mucosal inflammation. Impaired intestinal permeability 24 and a role for mucosal inflammation in regulating the gut-brain axis 25 have also been reported. However, it is well known that both mucosal inflammation and impaired intestinal permeability can be due to food hypersensitivity; 26 furthermore, many patients suffering from IBS report an association of symptoms with specific food ingestion. Numerous recent reports 18, 27, 28 have demonstrated that a subgroup of IBS patients suffers from FH and these subjects improve on elimination diet. However, the relationship between FH and IBS is still considered controversial and it is difficult to distinguish between these conditions because both IBS and FH with gastrointestinal symptoms often have the same clinical presentation. Furthermore, none of the available in vivo and in vitro allergy tests (ie, skin prick test and serum total IgE and specific IgE assays) have a good diagnostic reliability. 29 In this study we evaluated a large group of IBS patients and, using a rigorous diagnostic approach-based on elimination diet and DBPC challenge-identified those suffering from FH. Forty IBS patients were positive on DBPC challenge with cow's milk and/or wheat proteins and consequently a high percentage (40/160, 25%) of cases were diagnosed as FH. In these patients, symptom severity significantly regressed on elimination diet, while numerous previous treatments had not been effective. As 34 out of 160 patients (22%) showed gluten hypersensitivity, it would be interesting to place these subjects in the complex category of gluten sensitivity. 30 Previous works have demonstrated that gliadin can induce an increased intestinal permeability and innate immune cell activation. However, these studies NOTE. Reference values were: tryptase Ͻ 2.4 g/L; ECP Ͻ 1 g/g; calprotectin Ͻ 50 g/kg food allergen-specific IgE antibodies Ͻ 0.35 kU/L. The following antigens were used in the serum specific IgE assay: alpha-lactalbumin, beta-lactoglobulin, casein, wheat proteins. Positivity for 1 of them was considered as "positive assay," negativity for all was considered as "negative assay." on animal models observed these effects only in genetically susceptible subjects. 31, 32 In our study, the DQ2 or DQ8 human leukocyte antigen (HLA) haplotypes was present only in 22/ 40 (55%) of FH subjects, and it is noteworthy that most patients were suffering from both wheat-and cow's milk-protein hypersensitivity. Consequently, other non-DQ2/DQ8 related mechanisms should be investigated. As regards the fecal assays, the distribution of tryptase and ECP values was very interesting, whereas fecal calprotectin did not seem to be useful in distinguishing between FH and IBS.
The highest tryptase values were seen in FH subjects with progressively decreasing-and significantly different-levels in IBS and healthy control subjects. It is known that stimulation of mast cells with IgE-dependent or non-IgE-dependent agonists leads to the release of preformed and newly-synthesized inflammatory mediators. Therefore, tryptase, a serine proteinase, released almost exclusively by mast cells, may be suitable as a marker of mast-cell activation in patients with FH. Moreover, we showed that a high concentration of mast cell-derived proteins in the stools is characteristic of IBS, independently of coexistent FH 3,4,7-9 and, in fact, these patients showed significantly higher tryptase values than healthy controls. However, our data indicate the first evidence that fecal tryptase levels (and the underlining mast cell infiltration) is more intensive in FH than in IBS not related to FH. Further studies should clarify whether the elimination diet can improve the previously demonstrated mast cell mucosal inflammation and the neural damage which has been reported in IBS. 3, 4, [7] [8] [9] In fact, the relationship between FH and dismotility in pediatric patients has been clearly demonstrated. 20, [33] [34] [35] ECP might be as useful in FH patients as it is in patients with respiratory allergic diseases. 36 In our study, fecal ECP values were 2-fold higher in FH than in IBS patients or in healthy control subjects. Furthermore, IBS patients had ECP values virtually identical to healthy control subjects. Consequently, fecal ECP seems to be a specific marker of intestinal inflammation due to FH. Previous studies on ECP in adults with FH have included very few patients, prediagnosed as suffering from FH. Magnusson et al. showed an increase in fecal ECP in 13 FH patients after food challenge 37 and 8 of these patients fulfilled the Rome II criteria of IBS. However, in our study, ECP assay showed an overall sensitivity of 65% and we found elevated values in the "disease" control group, so in a clinical setting it may not distinguish between other organic disease and food hypersensitivity.
In conclusion, our study demonstrated that a relatively high percentage of IBS patients are actually suffering from FH and confirmed that this diagnosis is difficult as FH symptoms are very often very delayed. 38 In these patients tryptase and ECP are among the pivotal mediators of inflammation; consequently, tryptase and mast cells can be markers of FH rather than of prior gastroenteritis. Fecal assays of ECP may be useful in identifying FH patients among IBS-presenting subjects.
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